adsilico helps medical device makers find out how an implant will behave in the patients who rarely make it into clinical trials. Heart valves, stents and similar devices typically reach market on evidence from a few hundred participants, and those groups skew male: across 195 high-risk implant trials reviewed in JAMA Internal Medicine, women made up only a third of participants. Manufacturers are left with thin evidence on women, older patients and people with smaller or atypical anatomy until a device is already in wide use.
Its Virtual Chimera technology uses generative AI to build realistic virtual hearts and blood vessels from anonymised clinical scans, then runs physics-based simulations of a device inside each one under clinical oversight. Manufacturers can model a defined group, such as South Asian women aged 55 to 75, to decide which device sizes to make, spot higher-risk patients and target later trials, while gathering human-relevant evidence before animal studies begin.
Founded in 2024 by Sheena Macpherson, Nishant Ravikumar and Zeike Taylor and based at the university's Nexus innovation hub, adsilico has completed projects with heart valve and neurovascular device makers. It raised a £3.5M seed round from Northern Gritstone and Parkwalk in 2024, followed by a £10M Series A led by PXN Ventures in October 2026.